The FDA has approved icotrokinra, marketed as Icotyde, as the first oral peptide treatment for moderate to severe plaque psoriasis in adults and adolescents. Developed by Johnson & Johnson, the drug works by blocking the interleukin-23 (IL-23) receptor. This approval provides a new systemic option for patients aged 12 and older who weigh at least 40 kg, addressing a historical gap in oral therapies that balance efficacy with safety.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.